Centchroman

03/12/2008 - "Studies with Centchroman (CC) as a candidate anti-breast cancer agent are into phase III multicentric clinical trial in stage III/IV breast cancer. "
01/15/2018 - "Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis."
03/12/2008 - "Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells."
05/15/1989 - "Treatment with Centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman) has been evaluated in 4 male and 75 female patients with advanced breast cancer. "
05/15/1989 - "Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study."

07/01/2016 - "These results imply that centchroman is very effective in treating breast pain and can be prescribed as drug of first choice for mastalgia. "
07/01/2016 - "This study was conducted to evaluate the role of centchroman as a nonhormonal first-line treatment for moderate to severe mastalgia. "
07/01/2016 - "Centchroman as First-line Treatment for Mastalgia: Results of an Open-label, Single-arm Trial."
02/01/2019 - "It is therefore recommended to conduct well-designed RCTs to compare the effect of centchroman on mastalgia with that of a placebo or other medication."
02/01/2019 - "Since a meta-analysis could not be conducted and the quality of the papers was low, there was insufficient evidence to evaluate the effect of centchroman on mastalgia. "

05/15/1989 - "Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study."
04/01/2017 - "Centchroman (CC) or Ormeloxifene has been shown to induce apoptosis and cell cycle arrest in various types of cancer cells. "
11/01/2016 - "Centchroman (CC), a female oral contraceptive, has been shown to possess breast anti-cancer activities. "
06/01/2010 - "The tumor regression was monitored at different doses of centchroman alone ranging from 0 to 10 mg kg(-1) and with glycine soya from 1x10(4) to 5x10(4) mg kg(-1) per day until 5weeks treatment. "
02/01/2018 - "Centchroman (CC), an oral contraceptive has been found to exhibit anti-cancer potential against a wide range of cancer including breast cancer. "

10/01/2016 - "On fifth and sixth visit, 46 patients reported with pain score 0, one with pain score of 2 and four with pain score of 6. The efficacy of centchroman was found to be significant (p-value = 0.001). "
07/01/2016 - "The efficacy analysis of centchroman was done by comparing median Visual Analog Scale score, median pain duration and side effects over time among the two groups. "
06/01/2011 - "At 12 weeks 89.7% women achieved reduction in pain score to ≤3 in Centchroman group (pvalue 0.001). "
10/01/2016 - "Before starting treatment, four patients presented with pain score of 6 followed by, 37 patients with a score of 4 and 10 patients with a score of 2. All the patients were started on tab centchroman 30mg OD alternate days and were reviewed on weekly basis with Mastalgia chart and VAS pain score for three months. "
06/01/2011 - "Research Question- Is proportion of pain relief achieved by Centchroman similar to or inferior to that achieved by Danazol? "

10/01/2016 - "Our study proves that centchroman is a safe and cost effective drug with significant efficacy on regression of fibroadenosis and mastalgia with minimal side effect."
10/01/2016 - "Effectiveness of Centchroman on Regression of Fibroadenosis and Mastalgia."
10/01/2016 - "Fifty one patients with mastalgia/fibroadenosis were treated with centchroman 30mg once daily on alternate days for a period of 3 months and followed up weekly for six months with Mastalgia chart and Visual Analog Scale (VAS) pain score. "
10/01/2016 - "To find out the efficacy of centchroman, a Selective Estrogens Receptor Modulator (SERM) on regression of fibroadenosis and mastalgia. "